The Coronavirus Is Mutating. What Does That Mean for a

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
261
The Coronavirus Is Mutating. What Does That Mean for a Vaccine?
< >



Around the world, hope for a return to normalcy is pinned on a vaccine, the “ultimate weapon,” as it’s been called by officials like Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. But it’s still unclear how successful a vaccine against SARS-CoV-2, the virus that causes Covid-19, can be.

A lot will depend on how the virus mutates. Broadly, there are two ways mutations can play out.
Scenario 1: The coronavirus is unable to evade a vaccine

A successful vaccine could stop the virus dead in its tracks, but only if the virus doesn't mutate its way around the shot. Here's what scientists are watching for:

Like all viruses, SARS-CoV-2 is mutating as it passes from person to person. A “mutation” is just a change in a virus’s genetic code. Most mutations don’t really change how the virus functions.

Below is a glimpse at an imaginary virus. It’s doing what all viruses do: entering a cell, hijacking the cell’s machinery and using it to make many copies of itself.

Sometimes, small errors — or mutations — can show up in that replication. Those errors accumulate over time as the virus spreads from cell to cell and person to person.

Vaccines work by prompting the body to develop antibodies, which neutralize the virus by binding to it in a very specific way. Scientists are watching to see if mutations will affect this interaction. If they don't, then there is hope that a vaccine won't need constant updating

That same process has played out with our most effective vaccines, including the one against measles.

“Measles mutates just as fast as flu and coronavirus, but the measles vaccine from 1950 still works today,” said Trevor Bedford, a biologist at the Fred Hutchinson Cancer Research Center in Seattle.

To enter a cell, the measles virus uses certain of its proteins that are unable to mutate even slightly without breaking. The vaccine targets those parts, so any mutation that would evade the vaccine would mean that the virus can’t infect other cells.

The vaccine has the measles virus cornered.
Scenario 2: Mutations make vaccines less effective over time

But what if the virus doesn’t get cornered like measles? If the virus mutates in a way that prevents antibodies from binding, it could make a lasting, universal vaccine difficult to create.

Antibodies, which the body produces in response to a vaccine or an infection, work by binding to specific spots on a virus called antigens. If random viral mutations alter the shape of an antigen, it can make a vaccine less effective against the virus.

"What will happen in many viruses is you'll get infected by Strain A; your immune system learns to recognize that surface protein, but then the virus is able to mutate in such a fashion that it still performs its function but make it so that your antibodies against Strain A no longer recognize Strain B," Dr. Bedford said.

Here’s that scenario playing out on our fictional virus: The antibodies produced by the vaccine work on one strain but can’t bind to the other, rendering the vaccine ineffective.

That’s what happens with the flu: The virus’s antigens mutate so much that they evolve into different strains, each requiring a slightly different vaccine. Scientists continuously develop vaccines to target those new strains. In spite of that, the vaccines offer only partial immunity to the various flu strains that spread each year.

If that happens with the coronavirus, researchers will have to rush to produce and administer new vaccines as novel strains of the virus naturally arise.

It also reveals another quirk with how viruses behave: Some can respond to the immunity in the population they’re trying to infect. Over time, for example, many people develop immunity to at least some strains of the flu — either through fighting off infections or by getting vaccinated. But the virus keeps spreading. Here’s how.

For a brand-new virus like SARS-CoV-2, there is no widespread immunity. This virus is encountering few immune hosts who could halt its spread. Since the virus doesn’t need to change to survive, mutations that could modify the shape of the antigens — if they exist at all — are likely rare, and will stay rare.

But if people become immune to the dominant strain, either by fighting off the virus or through vaccination, the game changes. Versions of the virus with mutations that get around the population’s immunity are more likely to spread, and can then develop into new strains.

The takeaway: We’ll have to wait and see

Scientists know that SARS-CoV-2 is mutating.

Among the thousands of samples of the long strand of RNA that makes up the coronavirus, 11 mutations have become fairly common. But as far as we know, it’s the same virus infecting people all over the world, meaning that only one “strain” of the virus exists, said Peter Thielen, a molecular biologist with the Johns Hopkins Applied Physics Laboratory.

Only one of those common mutations affects the “spike protein,” which enables the virus to infect cells in the throat and lungs. Efforts to produce antibodies that block the spike protein are central to many efforts to develop a vaccine. Since the spike protein has changed little so far, some scientists believe that’s a sign that it can’t alter itself very much and remain infectious.

There’s still a lot about the virus we don’t know. We don’t even know if people are immune to the virus if they’ve caught it already, nor how long that immunity could last, though work is well underway to understand these things.

Mr. Thielen says it is still unclear how those mutations in the genome will ultimately affect countermeasures like a vaccine.

“We just have to keep looking,” he said.

Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vehicle Reliability Hinges on Design and Maintenance

Updated Category News Views 109

Why Some Cars Age Like Fine Wine—and Some Don't Here’s the thing—cars aren’t all made equal, and anybody who's tinkered around under the hood for a few years long knows that some vehicles just can’t hold it together as time marches on. Now, this ain't rocket science, but the truth is wrapped up in the complexity of designs and those pesky little maintenance...

Continue Reading
Pye-Barker's Bold Play in Florida Fire Safety Market

Updated Category News Views 5

A Strategic Spark in Fire Protection Well, here's a move that lights up the fire protection sector. Pye-Barker Fire & Safety, known for being the top dog in U.S. fire safety services, decided to scoop up St. John's Fire Equipment down in Florida. Let's just say, they're not putting out any fires here—more like stoking a strategic blaze. This acquisition positions...

Continue Reading
Xinjiang Co-op Elevates Walnut Farmers, Markets Expand

Updated Category News Views 86

From the Gobi Desert to the Global Market You ever hear about walnuts from the Gobi Desert? It sounds like a tale spun over too many drinks, but here we are, talking about folks in Xinjiang crafting an empire out of nuts. Not just any nuts, mind you—walnuts, lovingly nurtured under the sun and cold nights in Kuqa. They’ve carved out a niche in a corner of the world...

Continue Reading
Webull Legal Woes: Investors Eye Class Action Lead Role

Updated Category News Views 31

Legal Firestorm for Webull Sparks Investor Action Amidst the noise of digital investment platforms, Webull Corporation, ticker NASDAQ:BULL, finds itself not just trading stocks but facing a potential legal landmine. The clock's ticking for investors who've seen substantial losses to step up as lead plaintiff in a looming class action lawsuit. This isn’t some sideshow;...

Continue Reading
ROMTech Enhances Recovery Tech with New Website

Updated Category News Views 96

ROMTech Aims High with Website Revamp ROM Technologies, Inc., the medtech trailblazer, is taking a bold step by launching a fresh, spiffy corporate website. This overhaul isn't just about fancy graphics or slick user interfaces—though those are here in droves. We're talking a genuine commitment here to enhancing post-discharge recovery through home-based tech solutions....

Continue Reading
Ecovyst Ups Outlook Amid Strong Q3 Results

Updated Category News Views 93

A Bold Leap Forward Ecovyst, mighty in the sulfuric acid trade, just dropped news hotter than a griddle on a sizzling morning. Sales surged by 51% in Q3 to a solid $308.6 million, credited to smart moves and timely acquisitions. Not just puffery here; these folks are redirecting the narrative and it's showing in the numbers. Imagine a company selling parts of itself to...

Continue Reading
Yealink's Bold AI Vision for the Workplace Unveiled

Updated Category News Views 126

Yealink Sets the Stage for AI Conversations in Munich Ah, the buzz of innovation fills the air once again, as Yealink brings a dizzying array of tech bigwigs together at the Workplace Forward Summit in Munich. This ain't your regular business shindig—this is where the gears of the AI-powered future get some heavy oiling. Imagine 400 industry stalwarts, tech gurus,...

Continue Reading
Dizal Unveils Promising Data at ASH 2026

Updated Category News Views 99

Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...

Continue Reading
Domino's in Hot Water? Fiduciary Duty Concerns Loom

Updated Category News Views 97

Shareholder Rights On The Line You ever get that itch, the one that whispers something's off with a company? Well, that itch might be turning into a rash at Domino's Pizza, Inc. (NASDAQ: DPZ). Shareholders are being nudged to jump into the fray as Halper Sadeh LLC investigates potential wrongdoings by some of the pizza titan's bigwigs. The spotlight is on whether these...

Continue Reading
DraftKings Faces Scrutiny Over AI Use in Promotions

Updated Category News Views 93

DraftKings Under the Legal Microscope So here's a doozy that’s rattling through Beantown: DraftKings, the sportsbook titan, might be walking on financial eggshells thanks to their bold use of artificial intelligence. Shapiro Haber & Urmy, a doughty Boston legal jockey, is giving the high sign to users about a consumer class action investigation involving DraftKings'...

Continue Reading

Top 5 Most Recently Viewed Articles

Alliance Pharma's Recent Trading Disclosure Insights

Updated Category News Views 179

Recent Trading Disclosure by Alliance Pharma plc FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code Key Information (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree: Alliance Pharma plc

Continue Reading
Understanding Disclosure Trends with AXA Investment Managers

Updated Category News Views 179

Public Opening Position Disclosure by AXA Investment Managers AXA Investment Managers S.A. has made a significant disclosure styled as Form 8.3, which highlights the firm’s interests in Empiric Student Property plc. This document, often referred to within the financing and investment community, emphasizes transparency regarding ownership stakes in major entities. Key...

Continue Reading
New Diabetes Type 5 Announced Following Groundbreaking Research

Updated Category News Views 466

Recognition of Type 5 Diabetes: A New Era in Health Awareness Malnutrition-related diabetes has officially been acknowledged as a distinct type, termed type 5 diabetes. This recognition from the International Diabetes Federation signifies a significant advancement in understanding a disease that predominately impacts lean, malnourished young adults and teens in developing...

Continue Reading
OpenAI Launches o3: A Major Leap in AI Reasoning Models

Updated Category News Views 341

OpenAI Unveils Groundbreaking AI Model o3 Recently, OpenAI introduced its advanced reasoning model, o3, marking a significant development in artificial intelligence. This new model is touted as the successor to o1 and has generated considerable excitement in the tech community. OpenAI's focus on enhancing reasoning and coding abilities is evident in the latest offering,...

Continue Reading
Adaptimmune and Genentech Settle Agreement, Opening New Doors

Updated Category News Views 151

Adaptimmune and Genentech Settle Disputes Adaptimmune Therapeutics PLC (NASDAQ: ADAP) has officially reached a major settlement with Genentech Inc. and its parent company, F. Hoffmann-La Roche Ltd. This agreement resolves all disputes arising from their previous collaboration and marks an important milestone for Adaptimmune, particularly as the company emphasizes its...

Continue Reading